iBio Inc. reported financial results for the second quarter (Q2) and six months ended December 31, 2025. For Q2, revenue was zero, while revenue for the six months ended December 31, 2025, totaled 0.20 million. Research and development expenses were 4.28 million for Q2 and 7.83 million for the half year. Total stockholders' equity stood at 56.56 million as of December 31, 2025, with total liabilities and stockholders' equity at 64.39 million. During the period, iBio Inc. closed a 26 million private placement financing led by Frazier Life Sciences, with proceeds intended to advance key preclinical cardiometabolic programs, including IBIO-610 (activin E antibody), IBIO-600 (myostatin antibody), and bispecific programs targeting myostatin and activin A. The company reported progress in its preclinical pipeline and presented new scientific data at leading industry conferences. With the recent financing, iBio Inc. indicated its cash runway now extends into the third quarter of fiscal year 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. iBio Inc. published the original content used to generate this news brief on February 10, 2026, and is solely responsible for the information contained therein.